~~<i id='55575346A1'><strike id='55575346A1'><tt id='55575346A1'><pre id='55575346A1'></pre></tt></strike></i>~~

Home» Wikipedia» comprehensive

comprehensive

author：Wikipedia 2025-10-06 16:01:50 Page View：1831

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The woman behind the Dana Farber
Next article： Activists slam private health insurers over coverage restrictions

explore

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Readout Newsletter: Merck, J&J, and long Covid

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Chemotherapy shortages won’t get better under Biden’s latest plan

PresidentBidenspokeaboutsupplychainresilienceanddrugshortages.AlexWong/GettyImagesWASHINGTON—Preside

WSS

comprehensive

comprehensive

focus

explore

Chemotherapy shortages won’t get better under Biden’s latest plan